UNSPSC 51282010: Chloramphenicol sodium succinate

This classification denotes a protein synthesis inhibitor and antibiotic with the molecular structure C15H15CL2N2O8.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 872109HX6B chemically known as butanedioic acid, mono(2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl) ester, monosodium salt, (r-(r*,r*))-, but more commonly known as chloramphenicol sodium succinate, which bears US NIH Compound Identifier 298.

UNSPSC 51282010 Chloramphenicol sodium succinate is a Commodity code covering the supply of this specific antibiotic pharmaceutical product to state and local government health facilities. State and local procurement offices purchase chloramphenicol sodium succinate as part of broader generic pharmaceutical and over-the-counter product supply agreements that serve hospitals, clinics, correctional facilities, and other public health care settings. The issuing bodies under this code are typically state pharmacy cooperative purchasing alliances and state departments of health or administration that manage multistate pharmaceutical contracts on behalf of participating member agencies—counties, cities, school districts, and public health authorities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The procurement spans Minnesota, Oregon, and other participating MMCAP member states, with awarded vendors required to supply products through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must meet cGMP certification and Drug Supply Chain Security Act (DSCSA) compliance, hold contractual relationships with at least two of the three authorized wholesalers, maintain insurance including $5,000,000 commercial general liability coverage, and accept a 3 percent administrative fee on all contract purchases. The contract term spans two years for new responders with optional extensions through June 30, 2028, with evaluations weighted primarily on price competitiveness (75 percent) and secondarily on fixed pricing structure, administrative compliance, EDI capability, and fee acceptance.